# Pegvisomant And Sandostatin LAR Combination Study

> **NCT00068029** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 75 (—)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Pegvisomant/ Sandostatin LAR
- **DRUG:** Sandostatin LAR
- **DRUG:** Pegvisomant

## Key facts

- **NCT ID:** NCT00068029
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 75 (—)
- **Last updated:** 2008-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00068029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00068029, "Pegvisomant And Sandostatin LAR Combination Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00068029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*